Testing to treatment of BRAF-mutant metastatic NSCLC

In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metastatic non-small cell lung cancer (NSCLC), the testing strategies and first- and second-line treatment options for these patients.

The discussion focuses on which BRAF mutations to test for and when in the patient journey to test, before moving on to consider if NGS broad panel testing should be applied routinely for patients. Various treatments are considered, along with which decision criteria come into play when selecting a particular treatment.

The experts also discuss how to treat patients who have co-mutations detected during testing.

This is an informative podcast that culminates in some interesting key messages from two well-recognised Experts in the field of NSCLC.

Key clinical takeaways:

• Test all patients irrespective of histology and smoking history

• Test upfront so that more efficacious agents can be used earlier in the patient journey

• Next-generation sequencing is the gold-standard for testing wherever possible to ensure various targetable alterations are not missed

• There are effective BRAF + MEK inhibitor combination treatments available to treat our BRAFv600E-mutant metastatic NSCLC patients which have manageable safety profiles

Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/UZPBUAFOwcY

Download the trasncript and find out more about this programme and the featured experts here: https://cor2ed.com/lung-connect/programmes/testing-treatment-braf-mutant-metastatic-nsclc/

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/lungconnect/

X: https://x.com/lung_connect

This content is intended for healthcare professionals outside of the UK only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre

This podcast is developed by https://cor2ed.com/

Published November 2024

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC (uHCC) and take a deep dive into the different treatment options first-line focusing on IO and IO based combinations. Topics include:

• Current first-line systemic treatment options for uHCC
• Efficacy and safety of IO and IO combinations including practical aspects of identifying and managing immune-mediated AEs
• How to select between the two first-line IO-based treatment options based on clinical factors and practical considerations

Key clinical takeaways:

• Two first-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape
• Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies
• Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen ( single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up
• IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary.
• In clinical practice, treatment choice should be individualized, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/hcc-connect

X: https://x.com/hccconnectinfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme.

This podcast is developed by cor2ed.com

Published on November 2024

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available treatments for these patients.

They consider the prevalence and types of BRAF mutations in CRC patients and highlight the poor prognosis for these patients. The experts also cover the optimal time and methods for testing for BRAF mutations, as well as the targeted therapies currently available for BRAF-mutated CRC.

Several key trials are discussed, including the BEACON trial which resulted in encorafenib plus cetuximab being the standard of care in the second-line setting for patients with BRAF mutated CRC.

The discussion also looks at future studies including the BREAKWATER trial, which will provide important information about encorafenib plus cetuximab in the first-line for these patients, as well as the SEAMARK trial which will show the effects of adding immunotherapy to this combination.

Key clinical takeaways:

• BRAF mutations occur in around 10% of colorectal cancer patients and patients harbouring these have aggressive disease and a poor prognosis

• Targeted therapies are available for BRAF-mutated CRC so it is important to test patients early in their disease preferably with next-generation sequencing

• Encorafenib plus cetuximab are established as the standard of care in the second-line setting for BRAF-mutated CRC

• Doublet chemotherapy plus anti-VEGF is currently the preferred treatment in the first-line. The BREAKWATER trial will determine whether the combination of encorafenib plus cetuximab is a suitable first-line treatment option

Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/Pp7oAI9JW4A

Download the transcript and find out more about this programme and the featured experts here: https://cor2ed.com/gi-connect/programmes/braf-mutated-crc-testing-treatment/

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/giconnect

X: https://x.com/giconnectInfo

This content is intended for healthcare professionals outside of the UK only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre

This podcast was developed by https://cor2ed.com/

Published November 2024

Subscribe to this channel to stay up to date with new Independent Edu...

In this second episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins explore shared decision-making, between patient and physician.

The speakers discuss different treatment settings, including home vs hospital-based injections, as well as the importance of individualising treatment decisions, as there is often no standard therapy for patients with NETs. Finally, they look at some of the studies reporting patient preferences, and how the data can be used to inform patient decisions.

Prefer to watch and listen?
Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/?media=1

Watch the full video on YouTube https://youtu.be/2JYuPhc2jHg

Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k

Follow us on social media

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect

X: https://x.com/net_connectinfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen

This podcast is developed by cor2ed.com

Published July 2024

In this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins discuss the importance of communication and collaboration during consultations. This can include how to make a patient feel as comfortable and in control as possible, as well as recognising their goals and concerns.

The speakers share their real-life experiences of what makes a good consultation, from the perspectives of both a patient and a physician. They also explore the importance of support networks, individualising treatment, and the impact of NET and NET treatment options in daily life.

NETs are complex, rare diseases. Optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. Are you aware of how healthcare practitioners and patients can share decision- making? Or the recent data on how patients prefer to receive treatment?

In this first episode of a two-part podcast series, Dr Mohid S Khan and NET patient Sally Jenkins discuss shared decision-making in NET consultations and ways to help the patient in their journey.

Prefer to watch and listen?
Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/

Watch the full video on YouTube https://youtu.be/YgqrEnSePWg

Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k

Follow us on social media

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect

X: https://x.com/net_connectinfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen

This podcast is developed by cor2ed.com

Published July 2024

In the second episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss how to optimize treatment for people living with NETs and future developments in the field which may help to improve patient outcomes. The episode includes information on different treatment options and modalities, and well as best practice on identifying which patients may benefit most from particular treatments using available biomarkers.

Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-2/

Or go to the video on YouTube: https://youtu.be/zd_JvUmIhFg

We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen.

This podcast is developed by cor2ed.com

In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, and patient pathways, as well as look to future developments.

NETs are complex, rare diseases. Their optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. The best possible patient journey is impacted by regional differences in management strategies, referral pathways, and availability of diagnostic modalities and treatments.. Are you aware of the epidemiology of NETs and current best practices for diagnosis, referral strategies, and treatment for NETs? Or how regional differences can impact these? In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, patient pathways, as well as look to future developments.

Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-1/

Or go to the video on YouTube: https://youtu.be/6fKAxS4u-2o

We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen.

This podcast is developed by cor2ed.com

Do you understand the needs of different patient groups with colorectal cancer? Do you know about the barriers to treatment experienced by different ethnicities, socioeconomic groups and younger patients? In this insightful podcast facilitated by Oncology Brothers Drs Rahul and Rohit Gosain, Prof Tanios Bekaii-Saab and Ms Deneen Richmond provide their perspectives as a practising oncologist and a cancer survivor.

They discuss the different methods of communication required to build trust in patients from specific ethnic groups (African American, Hispanic and Asian American). They also talk about the unique challenges experienced by younger patients with colorectal cancer. Throughout the podcast the experts emphasise the importance of screening to facilitate early diagnosis and treatment.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/gi-connect/programmes/patient-populations-colorectal-cancer/

Or go to the video on YouTube: https://youtu.be/o-lr54-D9_g

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.

This educational podcast is developed by cor2ed.com